2011 16th International Solid-State Sensors, Actuators and Microsystems Conference 2011
DOI: 10.1109/transducers.2011.5969372
|View full text |Cite
|
Sign up to set email alerts
|

Delivery of an anti-cancer drug from a magnetically controlled MEMS device show cytotoxicity in PC3 and HUVEC cells

Abstract: We have developed a magnetically controlled MEMS drug delivery device for on-demand release of defined quantities of an anti-cancer drug, docetaxel (DTX). A drug-loaded micro reservoir (∅6mm×550µm) is sealed by a 40µm-thick elastic magnetic PDMS (polydimethylsiloxane) membrane with a laser-drilled aperture (~100×100µm 2 ). Discharge of the drug solution and the release rates are controlled by an external magnetic field. Controlled and reproducible release rates of DTX have been achieved for 35 days. We report … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2012
2012
2015
2015

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(5 citation statements)
references
References 6 publications
0
5
0
Order By: Relevance
“…Recent cancer therapy studies that used MEMS devices have focused their efforts on the development of new and safe drug delivery approaches 17, 51–54. These studies have shown that MEMS devices can potentially provide safer drug delivery approach for treating cancer in vitro and in vivo.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Recent cancer therapy studies that used MEMS devices have focused their efforts on the development of new and safe drug delivery approaches 17, 51–54. These studies have shown that MEMS devices can potentially provide safer drug delivery approach for treating cancer in vitro and in vivo.…”
Section: Resultsmentioning
confidence: 99%
“…In this work, we have demonstrated that despite their small size and loading volume, MEMS drug delivery devices can be employed for individualized drug delivery regimens to greatly improve the treatment in vitro outcome. To compare our device in regards of the 5 major challenges from MEMS drug delivery devices as mentioned earlier, a detail comparison analysis with other MEMS devices used for in vitro/in vivo cancer treatment studies17, 51–54 and the developed MEMS drug delivery approaches in the recent years is presented in Table 1 . With respect to miniaturization, although the presented device is not the smallest, it has a reasonable device size to drug volume ratio of 5.92 mm 3 /μl, allowing one to load a relatively high dosage of drug for clinical research studies on various in vitro and in vivo models.…”
Section: Resultsmentioning
confidence: 99%
“…The release rate exhibited sustained delivery for more than 35 days. 31 Clinical Application: Cancer Docetaxel was selected as a test drug to study the device release profile. Docetaxel is an antineoplastic agent that disrupts the mitotic spindle, causing cell death; it is used for the treatment of a variety of tumors, such as breast cancer.…”
Section: Magnetically Controlled Mems Drug Deliverymentioning
confidence: 99%
“…Magnetic field telemetry has also been used to perform wireless control of the implanted devices. Pirmoradi et al [12] have reported the development of a device whose drug reservoir is sealed with a magnetic membrane that possesses an aperture. Upon applying the magnetic field to the device, this will cause deformation to the membrane and consequently leading to the release of the drug molecules.…”
Section: Controllabilitymentioning
confidence: 99%
“…In particular, drugs delivered with conventional methods such as injection can be used in these implantable BioMEMS devices. These drug formulations can take the form of nanoparticle formulations for cancer therapy [9] to intravenous formulations [10,11] and even other potent substances such as hormones or painkillers [12]. Moreover, sensors can be incorporated into these BioMEMS devices where they can monitor the drug release profile and provide useful information for bioengineers and clinicians to optimize the drug therapy for the patients [8].…”
Section: Introductionmentioning
confidence: 99%